BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Ixion Biotechnology Comes Out From Under Q-Med AB Umbrella


10/19/2005 5:09:30 PM

ALACHUA, Fla.--(BUSINESS WIRE)--July 11, 2005--Ixion Biotechnology, Inc. closed a transaction in which it transferred assets, liabilities and employees relating to its oxalate technology to a subsidiary of Q-Med AB (listed on the Stockholm stock exchange as QMED.ST), its former majority shareholder. In the split out, Ixion received almost all of Q-Med's Ixion stock, $344,000 in cash, and debt forgiveness of over $6 million. Ixion also has retained over $175,000 in NIH grant funds for research. The biotechnology company, which had been a subsidiary of Q-Med, has returned to independent status. In the restructuring, Weaver Gaines, who was among Ixion's founders and had resigned as its Chairman in January 2005, has reassumed the title of President and CEO and rejoined the board. Kimberly Ramsey, formerly Ixion's vice president and comptroller, was elected vice president and chief financial officer. Jeff Opalko, the company's former lab manager, was rehired under his previous title. Fred Madec, PhD, a stem cell scientist, has been retained on the Ixion research staff, and Ammon B. Peck, PhD, was re-appointed as chief scientist.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->